UY40979A - Iimidazoarenos sustituidos, composición farmacéutica que los comprende y método para la formación de un complejo que los comprende - Google Patents

Iimidazoarenos sustituidos, composición farmacéutica que los comprende y método para la formación de un complejo que los comprende

Info

Publication number
UY40979A
UY40979A UY0001040979A UY40979A UY40979A UY 40979 A UY40979 A UY 40979A UY 0001040979 A UY0001040979 A UY 0001040979A UY 40979 A UY40979 A UY 40979A UY 40979 A UY40979 A UY 40979A
Authority
UY
Uruguay
Prior art keywords
imidazoarenes
substituted
complex
forming
pharmaceutical composition
Prior art date
Application number
UY0001040979A
Other languages
English (en)
Inventor
Cole Justin
Alyssa Miranda Johnson
Karki Rajesh
Meier Peter
Daniel Steven Palacios
Parthasarathy Saravanan
Patnaik Anup
Peukert Stefan
Kate Yaping Wang
Yang Fan
KRAUTWALD Simon
Alistair Edward Jack Ross
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY40979A publication Critical patent/UY40979A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulgan imidazoarenos sustituidos de Fórmula (I): . (I) o una de sus sales, hidratos, solvatos, racematos, enantiómeros, diastereómeros, o tautómeros farmacéuticamente aceptables; composición farmacéutica que los comprende y método para la formación de un complejo que los comprende.
UY0001040979A 2023-11-21 2024-11-18 Iimidazoarenos sustituidos, composición farmacéutica que los comprende y método para la formación de un complejo que los comprende UY40979A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363601402P 2023-11-21 2023-11-21

Publications (1)

Publication Number Publication Date
UY40979A true UY40979A (es) 2025-06-30

Family

ID=94080930

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040979A UY40979A (es) 2023-11-21 2024-11-18 Iimidazoarenos sustituidos, composición farmacéutica que los comprende y método para la formación de un complejo que los comprende

Country Status (5)

Country Link
CN (1) CN122295339A (es)
AR (1) AR134414A1 (es)
TW (1) TW202521543A (es)
UY (1) UY40979A (es)
WO (1) WO2025109474A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450555A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
US7429590B2 (en) * 2003-12-10 2008-09-30 Merck & Co. Inc. Antiprotozoal imidazopyridine compounds
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
MX2012003469A (es) * 2009-09-24 2012-04-19 Hoffmann La Roche Derivados de imidazopiridina o imidazopirimidina como inhibidores fosfodiesterasa 10a.
WO2014187762A1 (en) * 2013-05-23 2014-11-27 F. Hoffmann-La Roche Ag 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
CA2999852A1 (en) * 2015-09-29 2017-04-06 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting suv39h2

Also Published As

Publication number Publication date
CN122295339A (zh) 2026-06-26
WO2025109474A1 (en) 2025-05-30
AR134414A1 (es) 2026-01-14
TW202521543A (zh) 2025-06-01